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The DNA mismatch repair (MMR) system consists of a group of
highly conserved genes that stabilize the cellular genome by
correcting unpaired and mispaired bases during normal DNA
replication and by blocking recombination events between diver-
gent DNA sequences. Moreover, the human MMR system is
involved in DNA repair of physically/chemically damaged DNA
(Modrich and Lahue, 1996) and contributes to the control of the
G2 cell cycle check point by recognizing certain types of DNA
damage (Hawn et al, 1995). The relevance of the MMR system in
stabilizing the genome is illustrated by the demonstration that
MMR defective human cancer cell lines show a mutator pheno-
type characterized by increased DNA microsatellite instability and
hypermutability of expressed genes (Boyer et al, 1995; Glaab and
Tindall, 1997). Moreover, the disruption of this DNA repair
pathway in germinal cells of individuals affected by hereditary
non-polyposis colorectal cancer results in a strong predisposition
toward tumour development. Finally, the phenotype associated
with the loss of MMR function is similar to the phenotype
resulting from the accumulation of somatic mutations in a great
variety of sporadic human tumours (Eshleman and Markowitz,
1995). The MMR system in human cells is composed of at least
five genes: hMLH1, hMSH2, hMSH3, hPMS2 and GTBP (also
known as hMSH6) that are strictly related to key components of
the bacterial MutHLS mismatch repair system (for a review see
Modrich and Lahue, 1996). The available evidence suggests that
mismatch recognition in human cells is mediated by the two
known mismatch recognition complexes: the hMSH2–GTBP
heterodimer which acts on single base mispairs and loops of one or
two bases and the hMSH2–hMSH3 heterodimer that binds prefer-
entially loops of three and four bases (Acharya et al, 1996). The
binding of these mispair recognition complexes to DNA is likely
to form the substrate for interaction with other MMR protein
complexes such as the hMLH1–hPMS2 heterodimer. The process
is then completed by the excision and resynthesis of the DNA and
ligation of the newly synthesized strand. Besides the well-estab-
lished activity of the MMR system in correcting unpaired and
mispaired bases, several in vitro studies have demonstrated that
this DNA repair system can play a role in influencing tumour cell
susceptibility to DNA-damaging cytotoxic agents (Branch et al,
1995; Hawn et al, 1995; Fink et al, 1996). It has been demon-
strated that the hMSH2–GTBP complex and hMSH2 protein by
itself are able to recognize and bind cisplatin (CP)-DNA
intrastrand cross-links, which are the major DNA adducts
produced following treatments of cells with CP (Duckett et al,
1996; Mello et al, 1996; Yamada et al, 1997). Moreover, Aebi et al
(1996) reported that loss of the MMR genes results in acquired
resistance to CP in two human ovarian cancer cell lines and that
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are more resistant to CP than the sublines in which the MMR
defect has been complemented by chromosome transfer. Finally,
Brown et al (1997) suggested that loss of hMLH1 expression may
be critically involved in the development of CP resistance in
ovarian cancer patients. Although CP is widely used as one of
the most effective chemotherapeutic agents for treating ovarian,
testicular and several other solid tumours, the biochemical mecha-
nisms underlying the responsiveness of cancer cells to this drug
remain unknown.
To date, most of the attention has been focused on the incidence
and genetics of MMR defects while little is known about the
expression levels of the MMR proteins and their significance in
human cancer cell biology.
The aim of this study was to investigate the expression levels of
hMSH2 and GTBP proteins by Western blotting in a series of
previously untreated ovarian cancer patients. The correlation
between hMSH2 and GTBP levels and clinico-pathological
characteristics and response to CP-based chemotherapy have been
also investigated.
PATIENTS AND METHODS
This study was conducted on 20 previously untreated primary
ovarian cancer patients admitted to the Department of Gynecology
at the Catholic University of Rome. Patient characteristics are
listed in Table 1. The median age was 58 years (range 35–74).
Fourteen patients had stage III and six had stage IV disease
according to the International Federation of Gynecology and
Obstetrics (FIGO) classification. One tumour was graded as well-
differentiated (G1), three tumours as moderately differentiated
(G2) and six as poorly differentiated (G3) (World Health
Organization, 1979). Fifteen tumours were serous, three were
endometrioid, one was mucinous and one was undifferentiated
according to the World Health Organization histological typing of
ovarian cancer (Serov and Scully, 1973). All patients underwent
cytoreductive surgery. Surgical debulking was considered as
optimal (residual tumour ≤ 2 cm) in 13 patients and non-optimal
(residual tumour > 2 cm) in seven patients. Chemotherapy was
instituted 2–3 weeks after surgery. All patients received
chemotherapy containing CP (total CP dose = 500 mg).
Gynaecological examination, abdominopelvic ultrasonography,
CA-125 assay and radiological investigations, if necessary, were
performed monthly for the clinical assessment of response, which
was recorded according to the World Health Organization criteria
(World Health Organization, 1979). Approximately 1 month after
the last course of chemotherapy, clinically complete responders
underwent second-look laparoscopy. In laparoscopy negative
cases, second-look laparotomy was performed for the assessment
of pathological response. Of 17 patients evaluable for
chemotherapy response, nine showed a pathologically complete
response, two showed partial response and six showed no change
of disease or disease progression. In three clinically negative
patients, pathological assessment of response was not carried out
because of patient refusal of a second surgery.
Generation of anti-GTBP monoclonal antibodies
The mouse anti-GTBP monoclonal antibodies (mAb) 66H6 and
21F10, both IgGg1, were raised against the full-length recombi-
nant GTBP protein. Female balb/c mice were immunized with four
intraperitoneal and one intravenal injections. The spleen cells were
then fused with the myeloma line P3c63 Ag.8.653. Hybrids were
selected with enzyme-linked immunosorbent assay (ELISA) and
Western blots. They were then cloned by limiting dilution and the
individual clones were again screened as above. The selected
mAb-secreting lines were adapted to grow in roller bottles at a low
percentage (1%) of fetal calf serum. The antibodies were purified
from the culture medium by Gamma-plus Protein G Sepharose
(Pierce).
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Table 1 Patient characteristics according to origin of the tumour cells and hMSH2 and GTBP levels
Case Origin of Age Histotype Stage Grade Residual Chemotherapy hMSH 2 levels GTBP levels
tumour cells tumour response (a.u.) (a.u.)
1 Ascites 49 Serous III 3 <2 cm CR 3.009 1.623
2 Solid tumour 68 Serous III 3 <2 cm CR 2.5 1.3
3 Ascites 60 Serous IV 3 >2 cm CR 1.244 1.376
4 Solid tumour 35 Serous III 3 <2 cm CR 4.044 2.546
5 Solid tumour 56 Serous III 3 >2 cm CR 2.255 0.506
6 Solid tumour 50 Serous III 1 <2 cm CR 2.357 0.224
7 Ascites 69 Serous III 3 <2 cm CR 2.15 1.88
8 Ascites 72 Serous III 3 <2 cm CR 1.406 1.765
9 Ascites 51 Serous IV 3 <2 cm CR 0.667 0.508
10 Solid tumour 44 Serous III 3 <2 cm PR 2.982 1.413
11 Solid tumour 60 Endometrioid III 3 <2 cm PR 2.175 0.611
12 Ascites 70 Serous III 3 <2 cm NC-P 0 0
13 Solid tumour 52 Serous IV 3 >2 cm NC-P 0.389 0.28
14 Ascites 74 Undifferentiated IV 3 >2 cm NC-P 0.852 0.961
15 Solid tumour 46 Serous IV 3 >2 cm NC-P 1.543 0.427
16 Ascites 42 Serous III 2 <2 cm NC-P 1.092 1.624
17 Ascites 63 Serous III 3 >2 cm NC-P 1.557 1.6
18 Ascites 69 Endometrioid IV 3 >2 cm n.d. 1.63 1.112
19 Ascites 54 Endometrioid III 2 >2 cm n.d. 0.916 0.576
20 Solid tumour 65 Mucinous III 3 >2 cm n.d. 2.28 1.174
CR: complete response; PR: partial response; NC-P: no change of disease or disease progression; N.D.: not determined.Preparation of primary tumour cells
Tumour specimens and ascitic fluid were aseptically obtained
during surgery and tumour cells were prepared as previously
described (Scambia et al, 1992) with minor modifications. Briefly,
tumour cells were separated from ascitic fluid by centrifugation
and from solid tumour biopsies by mechanical and biochemical
(0.1% collagenase IV, Sigma, Milano, Italy) dissociation in Ham’s
F-12 medium supplemented with antibiotics under aseptic condi-
tions in a laminar flow hood. Cells were then filtered through a
sterile gauze to remove cell clumps and passed trough 25-gauge
needles in order to obtain a monocellular suspension. Cells were
separated on a Ficoll-hypaque gradient. Collected cells were
extensively washed in Hank’s balanced salt solution and resus-
pended in Ham’s F-12 medium. Tumour cells, assessed by
immunohistochemical staining for cytokeratin on cytospin prepa-
rations, were detected in a percentage ranging from 64 to 92%
(median: 73%).
Cell lines
The MMR-proficient human ovarian carcinoma cell line A2780,
the human cervical cancer cell line HeLa, and the MMR-deficient
human colorectal carcinoma cell lines LoVo (hMSH2-deficient)
and HCT-15 (GTBP-deficient) (Boyer et al, 1995) were used in
this study. All cultures were kindly provided by Dr P Karran
(Imperial Cancer Research Fund, Herts, UK) and were maintained
in RPMI-1640 medium supplemented with 10% fetal calf serum,
100 U ml–1 antibiotics and 0.3 mg ml–1 glutamine in a humidified
5% carbon dioxide incubator.
Preparation of cell lysates and Western blotting
analysis
Total cellular proteins were isolated blind from primary tumour
cells and from cell lines harvested during exponential growth, by
lysing the cells in 1% sodium dodecyl sulphate (SDS), 20 mM
EDTA, 10 mM Tris–HCl pH 8, 1.74 mg ml–1 phenylmethyl-
sulphonyl fluoride, 2.5 mg ml–1 leupeptin, chymostatin, pepstatin
and 0.2 mg ml–1 aprotinin. For hMSH2 and GTBP detection,
250 mg of each protein sample in 1 ´ SDS sample buffer were
separated onto a 6% SDS-polyacrylamide gel. After electroblot-
ting, the polyvinylidene difluoride (Millipore Co., Bedford, MA)
membranes were incubated with 6% non-fat dry milk in 1 ´ TBST
(0.1 M Trizma base, 0.15 M sudium chloride, 0.05% Tween-20,
pH 7.4) for blocking and then with the primary antibody in 3%
non-fat dry milk in 1 ´ TBST. Following incubation with an
alkaline phosphatase-conjugated goat anti-mouse antibody (Bio-
Rad Laboratories, Hercules, CA, USA), visualization of the bound
antibody was performed with the BCIP/NBT Phosphatase
Substrate System (Kirkegaard & Perry Laboratories, Gaithersburg,
MD, USA). The samples were also analysed by Western blot for
a-tubulin. Images of the blots were acquired with a Cohu CCD
camera and quantification of the bands was performed by Phoretix
1 D (Phoretix International Ltd, Newcastle upon Tyne, UK).
Band intensity was expressed as relative absorbance and hMSH2
and GTBP values were normalized to a-tubulin levels. Two to
four different Western blot analyses were performed on our
samples. The variability observed was never greater than 20%.
The following mAbs were used: amino-terminal Ab-1 mouse
anti-human MSH2 (Oncogene Science, Cambridge, MA, USA)
(at 1:100 dilution), Ab-1 mouse anti-human a-tubulin (Oncogene
Science, Cambridge, MA, USA) (at 1:100 dilution) and amino-
terminal 21F10 and 10E10 mouse anti-human GTBP (generated
as described above) (at 1:500 dilution).
Immunohistochemical analysis of hMSH2 in tissues
and cell lines
Immunohistochemical analysis was performed using Ab-1 anti-
hMSH2 antibody on frozen sections from histologically defined
neoplastic ovarian tissues, normal human colonic mucosa and on
cytospins of logarithmically growing A2780, LoVo and HCT-15
human cancer cell lines. Frozen tissues were obtained from
surgical resections and stored at –80°C until used. Cryostat
sections and cytospins were placed on SuperFrost slides and
fixed in 4% paraformaldehyde for 10 min at room temperature.
Endogenous peroxidase was blocked with 0.5% hydrogen
peroxide in absolute methanol for 30 min. The primary antibody
was applied for 1 h in 1:100 dilution and sequentially followed
by biotinylated anti-mouse immunoglobulin and horseradish
peroxidase-conjugated streptavidin (ABC-Vector Laboratories,
Burlingame, CA, USA) and then incubated in the chromogenic
substrate solution 3,3´-diaminobenzidine (Sigma, Milano, Italy)
for 10 min. Sections were lightly counterstained with Harris’s
haematoxylin, dehydrated, cleared and mounted. The percentage
of positivity of the neoplastic cells was evaluated by counting at
high magnification (1000 ´) at least five different areas of the
samples. Sample analysis was performed blind.
Statistical analysis
Pearson’s correlation test was used to analyse the relationship
between hMSH2 and GTBP levels. Kruskal–Wallis non-
parametric test was used to analyse the distribution of hMSH2
and GTBP protein levels according to the clinico-pathological
characteristics of the patients.
RESULTS
Characterization of anti-GTBP antibodies in cell lines
Among the anti-GTBP mAbs tested, 21F10 exhibited the best
specificity and reactivity. Western blot analysis performed with
21F10 showed a main band of approximately 160 kDa corre-
sponding to full-length GTBP in lysates from MMR-proficient
A2780 and HeLa cell lines and in the hMSH2-defective LoVo cells
(Figure 1). The amount of GTBP was considerably lower in LoVo
lysate than in A2780 and HeLa lysates. Full-length GTBP was not
detectable by Western blotting in the HCT-15 cells (Figure 1)
which contain frameshift mutations in GTBP gene resulting in
truncated proteins (Papadopoulos et al, 1995). However, this cell
line showed a marked immunohistochemical nuclear reactivity
with 21F10 anti-GTBP mAb (data not shown). This finding could
indicate the preserved immunoreactivity of the truncated GTBP
proteins since the frameshift mutations which generate a termina-
tion codon in HCT-15 cells (Papadopoulos et al, 1995) did not
affect the amino-terminal region recognized by our mAb. In the
absence of a characterized negative control for GTBP immuno-
staining in the literature, we considered the 21F10 anti-GTBP
mAb as inadequate for precise immunohistochemical assessment
of this protein.
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cancer cells and relationship with clinico-pathological
parameters
The expression levels of hMSH2 and GTBP in ovarian tumour
cells obtained from ascites (n= 10) and solid tumours (n= 10)
were examined by Western blot analysis with Ab-1 anti-hMSH2
and 21F10 anti-GTBP mAbs. A band of approximately 105kDa,
corresponding to hMSH2 and a band of 160kDa, corresponding to
GTBP (Figure 2) were observed in 19 out of 20 (95%) samples
analysed. A single case (ascitic cancer cells) did not show any
detectable band even when a twofold greater amount of protein
lysate was analysed (Figure 2, lane 8). This case was not consid-
ered in all statistical analyses described below. An additional
fainter band of approximately 80kDa was observed in some
samples analysed with the anti-hMSH2 mAb (Figure 2, lanes 3
and 9). This band has been previously described by Mello et al
(1996) and is believed to be a specific degradation product of the
hMSH2 protein. Moreover, a slower migrating band of approxi-
mately 120kDa was observed in Figure 2, lanes 1, 3, 4, 5 and 7: at
present, we are unable to explain the nature of this band and no
information about possible post-translational modifications of
hMSH2 is currently available. Table 1 shows hMSH2 and GTBP
levels according to the origin of tumour cells and the clinico-
pathological characteristics of the cases examined. The densito-
metric values of the hMSH2 and GTBP bands were normally
distributed and ranged from 0.389 to 4.044 (median 1.63)
absorbance units (a.u.) for hMSH2 and from 0.224 to 2.546
(median 1.174) a.u. for GTBP. hMSH2 and GTBP levels were
found to be directly correlated (r= +0.51, P= 0.025) (Figure 3).
hMSH2 expression was significantly higher in ovarian cancer
cells originating from solid tumours than from ascites (H= 4.5,
P= 0.033), whereas GTBP content did not significantly differ in
solid versus ascitic cancer cells (H= 0.96, P= 0.32).
The clinico-pathological characteristics and chemotherapy
response of the patients were not distributed differently according
to the origin of the tumour cells. No statistically significant differ-
ences were discovered in the distribution of hMSH2 and GTBP
levels with respect to the age of the patients, grade of differentia-
tion (G1–2 vs G3), histotype (serous vs non-serous) and extent of
surgical debulking (optimal vs non-optimal) (data not shown).
hMSH2 protein levels were significantly lower in stage IV patients
than in stage III patients (H= 7.35, P= 0.007) while GTBP tended
to be expressed at lower levels in stage IV cases (H= 3.01,
P= 0.08). Significantly lower hMSH2 levels were found in cancer
cells from non-responding patients than in cancer cells from
patients who achieved complete or partial response to CP-based
chemotherapy (H= 4.88, P= 0.027). GTBP levels were not
differently distributed according to chemotherapy response (data
not shown).
Immunohistochemical analysis of hMSH2 in cancer cell
lines and neoplastic ovarian tissues
Immunohistochemical analysis of hMSH2 with Ab-1 mAb was
performed in the MMR-proficient A2780 ovarian cancer cells,
in the hMSH2-defective LoVo colon carcinoma cells and in six
ovarian cancer specimens obtained from primary surgery from a
corresponding number of untreated ovarian cancer patients. Over
90% of A2780 cells exhibited an intense staining localized exclu-
sively in the nuclei while LoVo cells, which carry a deletion in
both alleles of the hMSH2 gene (Umar et al, 1994), did not show
immunoreactivity (Figure 4 A and B respectively). In all samples
of primary ovarian cancer, a specific nuclear immunoreaction with
Ab-1 was observed in the vast majority of the neoplastic cells
(over 80% of positive cells) (Figure 4 C, D). In three specimens of
normal human colonic mucosa used as a positive control for Ab-1
staining, immunohistochemistry revealed that hMSH2 immuno-
reactivity was confined to the glandular epithelium (data not
shown) as previously described by several authors using different
anti-hMSH2 antibodies (Wilson et al, 1995; Leach et al, 1996).
DISCUSSION
This is the first study analysing the expression levels of hMSH2
and GTBP proteins in a series of primary ovarian cancers. We
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GTBP
HeLa A2780 LoVo HCT15
Figure 1Western blot analyses of A2780, HeLa, LoVo and HCT-15 cell
lines performed with 21F10 mouse anti-human GTBP mAb. A main band of
about 160kDa, corresponding to full-length GTBP, is detected in the MMR
proficient A2780 and HeLa and in the hMSH2-defective LoVo cell lines. The
amount of GTBP was considerably lower in LoVo than that in A2780 and
HeLa cells. No detectable levels of GTBP were found in the GTBP-defective
HCT-15 cells
1 234567 8 9
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–80 kDa
Figure 2Representative Western blot analysis of hMSH2 and GTBP with
Ab-1 and 21F10mAbs of lysates of purified ovarian tumour cells (lanes 1–8)
and of A2780 ovarian cancer cell line (lane 9). A band of 105kDa,
corresponding to hMSH2, and a band of 160kDa, corresponding to GTBP,
are observable in all samples but one (lane 8). In the lower panel, the
samples were probed for a-tubulin
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Figure 3Correlation between hMSH2 and GTBP levels in primary ovarian
cancer cellsdemonstrated that hMSH2 protein is exclusively localized in the
nuclear compartment and is expressed in the vast majority of
neoplastic cells from primary ovarian tumours. These results are
consistent with those of Brown et al (1997), and with previous
demonstrations that microsatellite instability occurs with a low
prevalence in advanced stage ovarian cancer (King et al, 1995;
Arzimanoglou et al, 1996), indicating that the majority of tumour
cells from these patients carry a functional hMSH2 genes. Western
blotting analysis revealed that hMSH2 and GTBP display a wide
range of expression levels, suggesting that both these proteins
could play a role in the biology of ovarian tumour cells.
It has been previously demonstrated by Palombo et al (1995)
that the amount of hMSH2 and GTBP in the GTBP-deficient
HCT-15 and in the hMSH2-deficient LoVo cells, respectively, was
considerably lower that that in the MMR-proficient HeLa cells,
thus leading these authors to hypothesize that the two proteins are
unstable when not in a complex. Even though we cannot rule out
this possibility, the direct correlation between hMSH2 and GTBP
expression levels found in primary ovarian cancer cells is likely to
suggest that the expression of these two proteins may be regulated
by a common mechanism.
Only hMSH2 levels were found to significantly differ according
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Figure 4 Immunocytodetection (at magnification of 1000 ´) of hMSH2 protein with Ab-1 mAb in the MMR-proficient A2780 ovarian cancer cells (A) and in the
hMSH2-defective LoVo colon carcinoma cells (B). Over 90% of A2780 cells exhibited an intense staining exclusively localized in the nuclei while LoVo cells did
not show immunoreactivity. Representative immunohistochemical analysis of hMSH2 protein with Ab-1 mAb in primary ovarian cancer (C at magnification
200 ´, D at magnification 1000 ´). A specific nuclear immunoreaction for hMSH2 is present in over 80% of neoplastic cellsto the origin of the tumour cells, suggesting that hMSH2 levels
could be related to different biological characteristics of ascites-
derived with respect to solid tumour-derived cells. Ovarian tumour
cells which exfoliate from the surface of the solid tumour are
likely to develop distinct biological characteristics since they lose
cell–cell and cell–substrate interactions and, on the other hand,
develop the ability to grow in the intraperitoneal microenviron-
ment, which is particularly rich in cytokines and growth factors
(Kutteh and Kutteh, 1992), and to form metastatic implants on
peritoneal surface. However, in order to investigate whether
primary tumour and ascites represent two biologically distinct
entities, a multivariate analysis including other biologically rele-
vant parameters is needed and thus a larger series of cases is
required to adequately address this issue.
No statistically significant differences were found in the distrib-
ution of hMSH2 and GTBP levels according to age of the patients,
grade of differentiation, histotype and surgical debulking.
Conversely, we found that low hMSH2 protein levels were associ-
ated with poor chance of response to CP-based regimens. Our
findings cannot be seen merely as a consequence of the reduced
hMSH2 levels in stage IV patients since no difference in the type
of response according to stage of disease was found in our series.
Two different hypotheses could be considered: first, it has been
demonstrated that increased hMSH2 protein expression is associ-
ated with the entrance of resting cells into the cell cycle (Marra
et al, 1996). It is therefore conceivable that cancers expressing
low hMSH2 levels have a low proliferative fraction, which
is commonly considered to imply a low susceptibility to
chemotherapy. Alternatively, it has been demonstrated that the
amount of hMSH2 protein directly correlated with mismatch G-T
binding activity and that both parameters inversely correlated with
the level of drug resistance in various Chinese hamster ovary cells
showing different degrees of resistance to methylating agents
(Dosch et al, 1998). In this context, Mello et al (1996) previously
hypothesized that, similarly to the biochemical pathway proposed
for methylating agents, a mechanism that involves a futile cycle of
excision and resynthesis of damaged DNA and ultimately results
in cell death, could also be operative in the processing of CP
adducts. According to this model, the binding of hMSH2 to
CP-modified DNA would trigger the recruitment of other MMR
protein(s) causing misdirected repair attempts at sites of CP
damage. This abortive repair activity and/or the subsequent accu-
mulation of DNA strand breaks could provide a signal resulting in
growth arrest in the G2 phase of the cell cycle and subsequently
cell death. Thus, cancer cells with a relatively low content of
hMSH2 would be unable to increase DNA damage to an extent
sufficient to trigger cell death.
In conclusion, our study suggests a possible involvement of
hMSH2 in ovarian cancer cell biology and in influencing the
susceptibility to chemotherapeutic agents whereas the role of
GTBP remains unclear. However, further studies are required to
allow a better characterization of the function of the MMR system
in human cancer.
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